Regeneron Pharmaceuticals holds the cleaner structural position, with profitability as the main driver and valuation adding further support. Sanofi does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (REGN: Nasdaq 100, SAN.PA: STOXX 600).
Most of the lead runs through profitability, while valuation helps make the separation broader. The overall score gap is 23 points in favour of Regeneron Pharmaceuticals, Inc..
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
A solid similarity means the pair shares a clearly comparable long-term financial profile, even if individual dimensions still differ.
The match is driven mainly by revenue stability and margin trend.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Regeneron Pharmaceuticals, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where REGN and SAN.PA each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 11.2-point ROIC advantage.
Stability is the one area where Sanofi still pushes back materially — it is the steadier name on this dimension, which keeps the result from reading as one-way.
Profitability is the clearest driver, and valuation also supports Regeneron Pharmaceuticals, Inc.'s broader structural position.
Break down the REGN vs SAN.PA comparison across all dimensions with the full interactive tool.
Explore how REGN and SAN.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.